Vaccine: X最新文献

{"title":"How the African vaccine manufacturing accelerator can assist in strengthening Africa's response to global health challenges","authors":"Jeremiah Oluwamayowa Omojuyigbe, Olusegun Ayo Ade-adekunle, Ifeoluwa Ruth Atobatele, Feranmi Olalekan Adekunle","doi":"10.1016/j.jvacx.2024.100499","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100499","url":null,"abstract":"","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100499"},"PeriodicalIF":3.8,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259013622400072X/pdfft?md5=c610f503115654b81ed512bcf8c13461&pid=1-s2.0-S259013622400072X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of COVID-19 vaccination and menstrual health: A period-tracking app-based cohort study","authors":"Malini Ramaiyer ,&nbsp;Malak El Sabeh ,&nbsp;Jiafeng Zhu ,&nbsp;Amanda Shea ,&nbsp;Dorry Segev ,&nbsp;Gayane Yenokyan ,&nbsp;Mostafa A. Borahay","doi":"10.1016/j.jvacx.2024.100501","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100501","url":null,"abstract":"<div><h3>Background</h3><p>In initial COVID-19 clinical trials, menstrual health was not formally monitored, yet anecdotal reports of menstruation changes surfaced on social media. This study aims to assess the association between COVID-19 vaccines and menstruation using Clue, a period-tracking application.</p></div><div><h3>Study design</h3><p>A survey assessing demographics, menstrual health, stress levels, and COVID-19 vaccination was sent to Clue users between 12/7/2021 and 2/9/2022. Inclusion criteria were (1) 18 years or older (2) currently menstruating (3) not pregnant or breastfeeding since 1/2020. Menstrual data was collected for each participant. Users with cycle lengths more than 90 days were excluded. Cycle lengths were calculated for the 6-month average pre-vaccination (PRIOR), the cycle during which vaccination was administered (DURING), the cycle following DURING (AFTER1), and the cycle following AFTER1 (AFTER2). For periods, individuals were stratified based on whether vaccination was received during their menstrual period (DURING). Period lengths were additionally calculated for the 6-month average pre-vaccination (PRIOR), the first period following vaccination (AFTER1), and the period following AFTER1 (AFTER2). For unvaccinated participants, an index date (4/1/2022) was used to similarly designate menstrual cycles and periods. For each participant, cycle length changes for DURING, AFTER1, and AFTER2 compared to PRIOR were determined. Student’s <em>t</em>-test compared the mean of these changes between vaccinated and unvaccinated groups.</p></div><div><h3>Results</h3><p>Of 7,559 participants, 6,897 (91 %) were vaccinated. Compared to PRIOR, individuals vaccinated during their menstrual period demonstrated a statistically significant increase in the DURING period length, but not AFTER1 (p = 0.463) and AFTER2 (p = 0.692). No statistically significant changes were observed in period lengths of those vaccinated in between periods or in cycle lengths overall.</p></div><div><h3>Conclusion</h3><p>A small but statistically significant change in period length was observed only in individuals vaccinated for COVID-19 during their menstrual period. Providers can better counsel menstruating individuals to reduce vaccine misinformation.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"19 ","pages":"Article 100501"},"PeriodicalIF":3.8,"publicationDate":"2024-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000743/pdfft?md5=16d8784a1f8b1675c3a6528fcb90d634&pid=1-s2.0-S2590136224000743-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 vaccination in Canadian blood donors: Insight into donor representativeness of the general population","authors":"Sheila F. O'Brien ,&nbsp;Mindy Goldman ,&nbsp;Behrouz Ehsani-Moghaddam ,&nbsp;Wenli Fan ,&nbsp;Lori Osmond ,&nbsp;Chantale Pambrun ,&nbsp;Steven J. Drews","doi":"10.1016/j.jvacx.2024.100498","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100498","url":null,"abstract":"<div><h3>Introduction</h3><p>Blood donors world-wide were indispensable for monitoring anti-SARS-CoV-2 antibodies generated by infection and vaccination during the pandemic. Prior to the pandemic, donor vaccination behaviours were under-studied. We aimed to compare the percentage of Canadian blood donors with SARS-CoV-2 vaccination antibodies with the percentage of the general population who received at least one dose of vaccine each month during initial vaccine deployment. We also report donor attitudes towards SARS-CoV-2 vaccination.</p></div><div><h3>Methods</h3><p>Canadian blood donors were randomly selected for SARS-CoV-2 antibody testing over 2021 (N = 165,240). The percentage of donor samples with vaccination antibodies were compared with the percentage of general population who received at least one dose of vaccine in each month of 2021 except February. A random sample of Canadian blood donors were surveyed about vaccination intent and attitudes (N = 4,558 participated, 30.4 % response rate).</p></div><div><h3>Results</h3><p>The percentages of the general population vaccinated and donors with vaccination antibodies increased from 1 % to over 90 %. General population vaccination was greater early in vaccine deployment than donors (p &lt; 0.05), greater in donors than the general population by mid-2021 (p &lt; 0.05) but they were similar by the end of 2021. While 52.6 % of surveyed donors had received vaccine in May 2021, a further 41.1 % intended to when eligible. Most donors thought COVID-19 infection could be serious (83.5 %) and that it was important to be vaccinated even if previously infected (77.8 %).</p></div><div><h3>Conclusion</h3><p>Early pandemic vaccine prioritization to at-risk individuals and healthcare workers gave rise to higher general population vaccination percentages, while donors had higher vaccine antibody percentages as vaccine was deployed to progressively younger age groups. Since blood donors may be more willing to receive vaccination, under pandemic conditions they may be valuable for monitoring vaccination-induced seroprevalence.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100498"},"PeriodicalIF":3.8,"publicationDate":"2024-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000718/pdfft?md5=a4905d38c7dff62c05077a6009e8df90&pid=1-s2.0-S2590136224000718-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140951782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the vaccine potential of an in silico designed FepA peptide vaccine against Shigella flexneri in mice model","authors":"Md. Rayhan Ali ,&nbsp;Shahin Mahmud ,&nbsp;Md. Omar Faruque ,&nbsp;Md. Imam Hossain ,&nbsp;Mohammed Akhter Hossain ,&nbsp;K.M. Kaderi Kibria","doi":"10.1016/j.jvacx.2024.100493","DOIUrl":"10.1016/j.jvacx.2024.100493","url":null,"abstract":"<div><h3>Background</h3><p>Shigellosis is one of the significant causes of diarrhea in Bangladesh. It is a global health problem; approximately 1.3 million people die yearly from Shigellosis. The current treatment method, using different antibiotics against Shigellosis is ineffective. Moreover, it becomes a worrying situation due to the emergence of antibiotic-resistant pathogenic microbes responsible for these diarrheal diseases.</p></div><div><h3>Methodology</h3><p>Previous immunoinformatics study predicted a potential peptide from the Ferric enterobactin protein (FepA) of <em>Shigella</em> spp. In this study, we have chemically synthesized the FepA peptide. As a highly immunogenic, FepA peptide conjugated with KLH has been tested in mice model with complete and incomplete adjuvants as a vaccine candidate.</p></div><div><h3>Results</h3><p>Immunological analysis showed that all vaccinated mice were immunologically boosted, which was statistically significant (<em>P-</em>value 0.0325) compared to control mice. Immunological analysis for bacterial neutralization test result was also statistically significant (<em>P</em>-value 0.0468), where each ELISA plate was coated with 1 × 10⁷ <em>S. flexneri</em> cells. The Challenge test with 1 × 10¹² <em>S. flexneri</em> cells to each vaccinated and controlled mice showed that 37.5 % of control (non-vaccinated) mice died within seven days after the challenge was given while 100 % of vaccinated mice remained strong and stout. The analyses of the post-challenge weight loss of the mice were also significant (<em>P</em>-value 0.0367) as the weight loss percentage in control mice was much higher than in the vaccinated mice. The pathological and phenotypic appearances of vaccinated mice were also clearly differentiable compared with control mice. Thus all these immunological analysis and pathological appearances directly supported our FepA peptide as a potential immune booster.</p></div><div><h3>Conclusion</h3><p>This study provides evidence that the FepA peptide is a highly immunogenic vaccine candidate against <em>S. flexneri</em>. Therefore, these findings inspire future trials for the evaluation of the suitability of this vaccine candidate against Shigellosis.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100493"},"PeriodicalIF":3.8,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000664/pdfft?md5=82a32db0efd2143d6232750600f87f44&pid=1-s2.0-S2590136224000664-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141044088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population","authors":"Asma S. Albtoosh ,&nbsp;Randa Farah ,&nbsp;Khaled Al Oweidat ,&nbsp;Osama Mohammad Hussein ,&nbsp;Abdullah Ahmad Obeid ,&nbsp;Haitham Mounir Hamila ,&nbsp;Mousa Nizar Mousa Radwan ,&nbsp;Radi Feras Ahmad ,&nbsp;Hosam Marwan Masadeh ,&nbsp;Abdalla Ibrahim Hammad ,&nbsp;Ayman Mohammed Musleh ,&nbsp;Amal Ayman Fakhoury ,&nbsp;Farah Mahmoud Disi ,&nbsp;Yakoub Y.SH. Joudah ,&nbsp;Nathir Obeidat ,&nbsp;Keira P. Mason","doi":"10.1016/j.jvacx.2024.100495","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100495","url":null,"abstract":"<div><h3>Objective</h3><p>Breakthrough COVID-19 infections are common following immunisation with various types of vaccines. The patterns of infections have not been well established. We aimed to analyse the signs and symptoms of post vaccination infections in addition to the need for hospital admission, ER visit and supplemental oxygen in relation to age and gender.</p></div><div><h3>Methods</h3><p>A cross-sectional cohort study was conducted in JUH from March 2021 to August 2022, we interviewed 1479 individuals who are &gt;15 years of age and got a breakthrough infection. The statistical analysis was performed using STATA statistical software.</p></div><div><h3>Results</h3><p>Out of the 1479 cases, 50.2 % and 69.4 % were females and less than 45 years of age respectively. Symptoms of cough, fever and headache were reported by nearly 50 % of the patients, while one-third complained of dyspnoea. We found that participants older than 45 years had worse clinical outcomes (<em>P-value &lt; 0.001</em>). 13 deaths were identified in this study due to breakthrough infection, 92.3 % of them were older than 45 years (<em>P-value &lt; 0.001</em>). Participants ≥45 years who experienced a breakthrough infection of COVID-19 were 0.7 times less likely to be females using adjusted logistic regression.</p></div><div><h3>Conclusion</h3><p>This study indicates that despite more severe symptoms reported in younger patients, the major clinical outcomes were worse among older patients, which makes age a major risk for poor outcomes regardless of symptoms. Thus, older people should be evaluated carefully when presenting with mild symptoms of COVID-19 breakthrough infection. The study also confirms that there is no difference in the incidence of COVID-19 breakthrough infections between males and females. Prospective studies are needed to risk stratify COVID-19 breakthrough infections, which should take into account variants of the virus and comorbidities.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100495"},"PeriodicalIF":3.8,"publicationDate":"2024-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000688/pdfft?md5=10e497b375e3d278fbf14cb85f6e4f30&pid=1-s2.0-S2590136224000688-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140878815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Area and individual level analyses of demographic and socio-economic disparities in COVID-19 vaccination uptake in Belgium","authors":"Pierre Hubin ,&nbsp;Laura Van den Borre ,&nbsp;Toon Braeye ,&nbsp;Lisa Cavillot ,&nbsp;Matthieu Billuart ,&nbsp;Veerle Stouten ,&nbsp;Léonore Nasiadka ,&nbsp;Elias Vermeiren ,&nbsp;Izaak Van Evercooren ,&nbsp;Brecht Devleesschauwer ,&nbsp;Lucy Catteau ,&nbsp;Joris A.F. van Loenhout","doi":"10.1016/j.jvacx.2024.100496","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100496","url":null,"abstract":"<div><p>Vaccination has played a major role in overcoming the COVID-19 pandemic. However, vaccination status can be influenced by demographic and socio-economic factors at individual and area level.</p><p>In the context of the LINK-VACC project, the Belgian vaccine register for the COVID-19 vaccination campaign was linked at individual level with other registers, notably the COVID-19 laboratory test results and demographic and socio-economic variables from the DEMOBEL database. The present article aims at investigating to which extent COVID-19 vaccination status is associated with area level and/or individual level demographic and socio-economic factors. From a sample of all individuals tested for SARS-CoV-2 (LINK-VACC sample) demographic and socio-economic indicators are derived and their impact on vaccination coverages at an aggregated geographical level (municipality) is quantified. The same indicators are calculated for the full Belgian population, allowing to assess the representativeness of the LINK-VACC sample with respect to the impact of demographic and socio-economic disparities on vaccination uptake.</p><p>In a second step, hierarchical models are fitted to the individual level LINK-VACC data to disentangle the individual and municipality effects allowing to evaluate the added value of the availability of individual level data in this context.</p><p>The most important effects observed at the individual level are reflected in the aggregated data at the municipality level. Multilevel analyses show that most of the demographic and socio-economic impacts on vaccination are captured at the individual level, although accounting for area level in individual level analyses improve the overall description.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100496"},"PeriodicalIF":3.8,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S259013622400069X/pdfft?md5=ec0c7bc7d5eae7542869c5bab39f05d7&pid=1-s2.0-S259013622400069X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140914144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults","authors":"Murdo Ferguson ,&nbsp;Alexander Murray ,&nbsp;Lew Pliamm ,&nbsp;Lars Rombo ,&nbsp;Johan Sanmartin Berglund ,&nbsp;Marie-Pierre David ,&nbsp;Nathalie De Schrevel ,&nbsp;Franck Maschino ,&nbsp;Shady Kotb ,&nbsp;Aurélie Olivier ,&nbsp;Veronica Hulstrøm","doi":"10.1016/j.jvacx.2024.100494","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100494","url":null,"abstract":"<div><h3>Background</h3><p>Previous phase 3 studies showed that the AS01_E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots.</p></div><div><h3>Methods</h3><p>This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded.</p></div><div><h3>Results</h3><p>A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94–1.21), 0.92 (0.81–1.04), and 0.87 (0.77–0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these–a case of atrial fibrillation–was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related.</p></div><div><h3>Conclusion</h3><p>This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile.</p><p><span>ClinicalTrials.gov</span><svg><path></path></svg>: NCT05059301.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100494"},"PeriodicalIF":3.8,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000676/pdfft?md5=f84b7fc005af8f59381438c7188a7918&pid=1-s2.0-S2590136224000676-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140880346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of measles vaccine virus and measles-specific immunoglobulin M in children vaccinated against measles-mumps-rubella during measles outbreak","authors":"Euri Seo ,&nbsp;Yun-Jung Chang ,&nbsp;Jae Woo Chung ,&nbsp;Yoon-Seok Chung ,&nbsp;Seong Yeon Park","doi":"10.1016/j.jvacx.2024.100491","DOIUrl":"10.1016/j.jvacx.2024.100491","url":null,"abstract":"<div><p>Information regarding the detection perioid of measles vaccine virus (MeVV) RNA in human nasopharyngeal samples and measles-specific antibodies following measles-mumps-rubella (MMR) vaccination is limited. During contact tracing for a measles outbreak at a hospital in Republic of Korea, 4 out of 206 children vaccinated with MMR underwent real-time RT-PCR assay for measles and measles-specific antibodies test. Measles virus RNA was detected in 2 children, all of which was vaccine virus strain RNA (genotype A). In a healthy 27-month-old boy, MeVV RNA was detected 448 days after MMR vaccination. Measles-specific IgM was positive 1097 days following vaccination in a 4-year-old girl. MeVV RNA and measles-specific IgM were detected for a considerable period following primary MMR vaccination. Physicians should exercise caution when interpreting positive RT-PCR results for MeVV or measles-specific IgM from a child with measles-associated symptoms who has been recently vaccinated against measles.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100491"},"PeriodicalIF":3.8,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000640/pdfft?md5=d2cb6ac8bde6389209d82606a53d1c79&pid=1-s2.0-S2590136224000640-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140783663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case-finding for HPV vaccination eligibility within a dental office with concurrent development of a dialogue tool","authors":"Cheryl E. Cable ,&nbsp;Kaitlyn E. Watson ,&nbsp;Ross T. Tsuyuki","doi":"10.1016/j.jvacx.2024.100492","DOIUrl":"10.1016/j.jvacx.2024.100492","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;Human papillomavirus (HPV) immunization can prevent cancers, but uptake has been incomplete (and worse with the COVID-19 pandemic). Dental clinicians already screen for oral cancers, many of which are caused by HPV, and could identify vaccination candidates, but this requires a case-finding strategy.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;The purpose of this study was (1) to develop and test a case-finding approach to identify patients who were candidates for HPV vaccinations, (2) to test an HPV vaccination intervention by dental professionals on vaccination uptake.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;Design: Prospective, non-randomized feasibility case finding study with a 4-week enrollment period and a 6 week follow up period in general dental offices.&lt;/p&gt;&lt;p&gt;Setting: Two general and non-commercial dentistry offices in Edmonton, Alberta Canada.&lt;/p&gt;&lt;p&gt;Subjects: Consecutive scheduled (non-emergent) patients who met the Health Canada criteria for HPV vaccination: immunocompetent males and females aged 9–45 years and those who are immunocompromised. Consent for the discussion was obtained from each subject or parent.&lt;/p&gt;&lt;p&gt;Intervention: Scheduled dental patients meeting the inclusion criteria were flagged by a research assistant who reviewed the appointment schedule each week for 4 weeks. For these subjects, dental clinicians (dentists and dental hygienists) used our Dental Dialogue Tool to discuss HPV vaccination and answer questions. Participating patients who consented to receive the HPV vaccine were given a prescription by the attending dentist and were directed to follow-up with a local pharmacy to have the vaccine administered. Each participant that was provided with an HPV prescription was contacted after 6 weeks to identify if they received the first dose of vaccine.&lt;/p&gt;&lt;p&gt;Outcomes: Yield of our case-finding strategy and receipt of a patient’s first HPV vaccine dose during 6 weeks post vaccine prescription.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Our case-finding strategy assessed 656 scheduled patients over 4 weeks. From this screening,179 (a case-finding yield of 20.4 %), were candidates for HPV vaccine discussion. Forty-three of these 179 patients (24 %) were already vaccinated.. Two patients (1.1 %) did not consent to be spoken with and 134 (74.8 %) consented to the HPV vaccine discussion.. Forty-eight of 134 patients (35.8 %) of patients accepted a prescription from the dentist after speaking with the dental clinician. Ultimately, 8/48 (16 %) (patients received their first dose of the HPV vaccine by the 6 week of follow-up call. However, this is only 4.5 % (8/177) of those patients who did consent for the discussion of HPV cancers and vaccination from their dentist.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;p&gt;We demonstrated that case-finding for HPV vaccine candidates in general dental offices was feasible, with a reasonable yield. While the dental dialogue tool was described as a great resource to explain the facts and answer que","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100492"},"PeriodicalIF":3.8,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000652/pdfft?md5=4c9ce8f38f3d10ca8fb82203c727746a&pid=1-s2.0-S2590136224000652-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccine hesitancy prevalence in Mexico: A systematic review and metanalysis","authors":"Diego Ramonfaur ,&nbsp;Rupali J. Limaye ,&nbsp;David E. Hinojosa-González ,&nbsp;Francisco J. Barrera ,&nbsp;Gloria P. Rodríguez-Gómez ,&nbsp;Carlos Castillo-Salgado","doi":"10.1016/j.jvacx.2024.100488","DOIUrl":"https://doi.org/10.1016/j.jvacx.2024.100488","url":null,"abstract":"<div><h3>Background</h3><p>Vaccine hesitancy (VH) is a recognized threat to public health that undermines efforts to mitigate disease burden. This study aims to gather available evidence regarding COVID-19 VH in Mexico, estimate the prevalence of VH, and its determinants to inform policymaking in this country.</p></div><div><h3>Methods</h3><p>Following PRISMA guidelines, a systematic review of the MEDLINE literature, articles that estimated the prevalence of COVID-19 VH in Mexico were included in the analysis to obtain a pooled estimate. We used a binomial-normal model for <em>meta</em>-analysis of proportions (i.e., generalized linear mixed model) to perform the metanalysis. We then performed a narrative review of COVID-19 VH in Mexican subpopulations.</p></div><div><h3>Results</h3><p>Seven studies met inclusion criteria. We estimated a pooled prevalence of COVID-19 VH of 16 % (95 % CI: 11–23 %) in Mexico. We found an association between VH and demographic characteristics, intrinsic vaccine factors, and beliefs. Subgroup analyses from specific studies suggested that patients with clinical conditions such as breast cancer or rheumatologic diseases had a higher prevalence of VH.</p></div><div><h3>Conclusions</h3><p>VH is a highly complex and dynamic phenomenon in Mexico. Characterizing and understanding COVID-19 vaccine hesitancy in the Mexican population helps target future policy interventions to mitigate the spread and impact of infectious diseases. The implications of VH differ among groups that may be at higher risk of severe disease, underscoring the importance of prompt research among these groups as well as targeted interventions to address VH.</p></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"18 ","pages":"Article 100488"},"PeriodicalIF":3.8,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590136224000615/pdfft?md5=d2d033f22d59ac6c8624f9dbfeff3450&pid=1-s2.0-S2590136224000615-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140631807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}